MX9306215A - Composicion novedosa para terapia peroral de un deterioro de la cognicion y un proceso para la fabricacion de la misma. - Google Patents

Composicion novedosa para terapia peroral de un deterioro de la cognicion y un proceso para la fabricacion de la misma.

Info

Publication number
MX9306215A
MX9306215A MX9306215A MX9306215A MX9306215A MX 9306215 A MX9306215 A MX 9306215A MX 9306215 A MX9306215 A MX 9306215A MX 9306215 A MX9306215 A MX 9306215A MX 9306215 A MX9306215 A MX 9306215A
Authority
MX
Mexico
Prior art keywords
cognition
deterioration
manufacture
same
novel composition
Prior art date
Application number
MX9306215A
Other languages
English (en)
Inventor
Jay Weiss
Nouman Muhammad
Gary D Alonzo
Shirley Yang
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MX9306215A publication Critical patent/MX9306215A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

Se formula una composición sólida para la terapia peroral del deterioro de la cognición para estabilizar el fármaco lábil a los ácidos, C1-979 HC1, mediante la colocación de una capa de una mezcla del mismo con un aglomerante sobre mini esferas de azúcar, y con un recubrimiento final de la estructura con una cubierta de protección.
MX9306215A 1992-10-06 1993-10-06 Composicion novedosa para terapia peroral de un deterioro de la cognicion y un proceso para la fabricacion de la misma. MX9306215A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95732292A 1992-10-06 1992-10-06

Publications (1)

Publication Number Publication Date
MX9306215A true MX9306215A (es) 1994-07-29

Family

ID=25499416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306215A MX9306215A (es) 1992-10-06 1993-10-06 Composicion novedosa para terapia peroral de un deterioro de la cognicion y un proceso para la fabricacion de la misma.

Country Status (9)

Country Link
US (1) US5650174A (es)
EP (1) EP0662832A1 (es)
JP (1) JPH08502264A (es)
AU (1) AU674175B2 (es)
CA (1) CA2142727A1 (es)
MX (1) MX9306215A (es)
NZ (1) NZ257018A (es)
WO (1) WO1994007494A1 (es)
ZA (1) ZA937382B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521322A (ja) * 1998-07-23 2002-07-16 ノボ ノルディスク アクティーゼルスカブ 安定な医薬製剤の製造のための湿式顆粒化方法
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
JP2007501256A (ja) 2003-08-06 2007-01-25 ムルイェ、ニルマル 水溶性薬物を含有する医薬組成物
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007025177A2 (en) * 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP5274261B2 (ja) * 2006-12-07 2013-08-28 第一三共株式会社 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
CN101600431B (zh) * 2006-12-07 2011-09-07 第一三共株式会社 具有改进贮存稳定性的药物组合物
KR101442862B1 (ko) * 2006-12-07 2014-09-22 다이이찌 산쿄 가부시키가이샤 만니톨 또는 유당을 함유하는 고형 제제
KR101665705B1 (ko) * 2006-12-07 2016-10-12 다이이찌 산쿄 가부시키가이샤 안정성이 개선된 필름 코팅 제제
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
IL81610A (en) * 1986-02-27 1990-12-23 Roussel Uclaf Derivatives of 1,2,5,6-tetrahydropyridin-3-carboxaldehyde oxime,their preparation and pharmaceutical compositions containing them
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4786648A (en) * 1986-12-08 1988-11-22 Warner-Lambert Company O-substituted tetrahydropyridine oxime cholinergic agents
GB8702411D0 (en) * 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US4925674A (en) * 1988-08-25 1990-05-15 Himedics, Inc. Amoxicillin microencapsulated granules
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
AU5297693A (en) * 1992-10-06 1994-04-26 Warner-Lambert Company Stabilized compositions containing 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxyaldehyde-o-meth yl-oxime
US5362860A (en) * 1993-02-01 1994-11-08 Warner-Lambert Company Neutral stabilization complex for CI-979 HCl, a cognition activator
US5424301A (en) * 1993-02-01 1995-06-13 Warner-Lambert Company Starch stabilized o-substituted tetrahydropyridine oxime cholinergic agents

Also Published As

Publication number Publication date
AU5321794A (en) 1994-04-26
NZ257018A (en) 1996-02-27
CA2142727A1 (en) 1994-04-14
AU674175B2 (en) 1996-12-12
WO1994007494A1 (en) 1994-04-14
JPH08502264A (ja) 1996-03-12
ZA937382B (en) 1994-04-29
EP0662832A1 (en) 1995-07-19
US5650174A (en) 1997-07-22

Similar Documents

Publication Publication Date Title
MX9306215A (es) Composicion novedosa para terapia peroral de un deterioro de la cognicion y un proceso para la fabricacion de la misma.
NO150206C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive hoeyredreiende spiro-hydantoinforbindelser
IT1076469B (it) Procedimento per la carbo di immidazione parziale dei gruppi di isocianato di isocianati organici
IT1121673B (it) Procedimento per la produzione di composti silicio organici solforati
NO155133C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme dicykliske forbindelser.
NO171852C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cefemforbindelser med to substituerte 5-leddede ringer
IT1065406B (it) Nuova composizione di catalizzatore supportato e procedimento per la preparazione di esteri organici che usa tale catalizzatore
NO914490L (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme tricykliske forbindelser
NO151040C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-halogenpyrimid-2-oner
AR016551A1 (es) Derivados de 2-oxindol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos
TR199900644T2 (xx) 1,2,3,4-Tetrahidro-benzofuro $3,2-c] piridin t�revleri.
JPS536410A (en) Medical composition containing organic derivative of montmorillonite
JPS5697236A (en) Manufacture of organic compound
IT1098275B (it) Procedimento per la produzione di idrocarburi aromatici ad elevata purezza
NO164172C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tricykliske tienokondenserte forbindelser.
NO780743L (no) Fremgangsmaate for fremstilling av farmakologisk aktive benzylpyrimidiner
IT1068429B (it) Procedimento per la produzione di fogli composti
NO149208C (no) Analogifremgangsmaate for fremstilling av nye, terapeutisk aktive benzodiazepiner
DK257083D0 (da) Mikroorganismestammen chromobacterium violaceum, farmaceutisk aktive forbindelser fremstillet med stammen, fremgangsmade til fremstilling af forbindelserne og disses anvendelse som laegemidler
NO142524C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive cykloheksylfenyl-derivater
BE786596A (fr) Purification d'isocyanates organiques
DE3068652D1 (en) 6-keto pge1 compounds, their preparation and therapeutic application, pgi1 compounds
PT97017A (pt) Processo para a preparacao de 1-alquil-,1-alquenil- e 1-alquinilaril-2-amino-1,3-propanodiois e de composicoes farmaceuticas que os contem
JPS5697246A (en) Manufacture of organic compound
NO142035C (no) Analogifremgangsmaate til fremstilling av terapeutisk virksomme substituerte triazoler

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees